Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CA9 | Q16790 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 6/20 | 0.33 |
| ▸ | MMP9 | P14780 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 4/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3030207 | 0.77 | TDP1 (0.48) | CA2CA9MMP2MMP9CA1 | |
| SCHEMBL12994623 | 0.75 | MAPT (0.48) | CA2CA9MMP2MMP9CA1 | |
| SCHEMBL5760689 | 0.73 | ENPP2 (0.50) | CA2CA9CA1CA12ALDH1A1 | |
| SCHEMBL1334344 | 0.73 | ENPP2 (0.50) | SMN1; SMN2CA2CA9CA1CA12 | |
| SCHEMBL1899321 | 0.73 | CA2 (0.40) | SMN1; SMN2CA2CA9MMP2MMP9 | |
| SCHEMBL2513199 | 0.72 | NR3C2 (0.44) | SMN1; SMN2CA2CA9CA12ALDH1A1 | |
| SCHEMBL26321893 | 0.72 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13319989 | 0.70 | CA2 (0.47) | SMN1; SMN2APLNRCA2ALDH1A1HTT | |
| SCHEMBL12169725 | 0.70 | CA1 (0.47) | SMN1; SMN2CA2CA9CA1ALDH1A1 | |
| SCHEMBL2581495 | 0.69 | TDP1 (0.39) | CA2CA9CA1CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2013-02-21 | — | — | US | claimed |
| EP-2533636-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | Mapi Pharma Limited (IL) | 2012-12-19 | — | — | EP | claimed |
| WO-2011099010-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA HOLDINGS (CYPRUS) LIMITED (CY) | 2011-08-18 | — | — | WO | claimed |
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2013-02-21 | — | — | US | disclosed |
| EP-2533636-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | Mapi Pharma Limited (IL) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011099010-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA HOLDINGS (CYPRUS) LIMITED (CY) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | CYP2F1, CYP4F3, CYP2D6 | SMN1; SMN2 2488/4885APLNR 3910/4885CA2 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.